TOKYO -- Japan's Fujifilm Holdings will spend $1.6 billion (about 200 billion yen) to nearly quadruple its capacity for biopharmaceutical products by upgrading U.S. and European plants, Nikkei has learned.
Fujifilm intends to boost its contract manufacturing of biopharmaceuticals for startups and large drug companies that aim to develop highly effective treatments for cancer, diabetes and other diseases.
